Top 50 Biotech Startup Investors in Sweden in November 2024

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

EIR Ventures is a new Life Science Venture Group in the Nordics.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

We help great minds unleash their full potential!

Norrlandsfonden is a foundation that promotes the development of companies with growth ambitions. They offer flexible prime loans for new establishments, development, and expansion. They provide the opportunity for offensive and forward-looking investments and enable companies and people to grow.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Joyance Partners is the first venture fund supporting companies that deliver Delightful Moments derived from science - a new, transformative cycle of human experience that we see as one of the greatest investment opportunities in decades.

Landegren Gene Technology

Länsförsäkringar is a Swedish group of public insurance companies.

Augmenta will invest in early stages of companies with unique products and strong growth potential.When portfolio companies have a fully developed product or service that is ready for commercialization, will Augmenta to leave their interests in portfolio companies. Exactly when this will happen will vary and depend on each company's uniquesituation.

Almi Invest GreenTech is a venture capital company and an active start-up investor.

Sting – Stockholm Innovation & Growth enables talented people to turn their ideas into sustainable businesses. The support they offer includes qualified coaching in business development, a business angel network, a venture capital fund, a recruitment service, and an international network of investors, business contacts and experts. Itcontribute to the success of Sweden’s future technology companies by helping them to grow and compete internationally.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Beijer Ventures is an investment Firm.

Impacting the future of medicine.

Kale United offers a portfolio of over 75+ plant-based game changers

KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.

Glass Wall Syndicate invests in companies and products that will make a difference in the lives of animals, people, and the planet. It helps grow companies in this space by providing them with capital, resources, mentorship, and other forms of support.The firm is consists of a group of venture capitalists, foundations, trusts, non-profits, andindividual investors who share a similar investment thesis and want to accelerate mainstream adoption of products and services that will make a difference in the lives of animals, people and that are better for the planet.

Per Båtelson

Premium domains add authority to your site. Transparent pricing. 1 year WHOIS privacy included. 30-day money back guarantee.

Pan-european early-stage deep-tech VC

Investing in the crazy before it becomes normal

Falkenbergs Sparbanks Foundation

Klimatet Invest is to create long-term value growth by investing relatively early in idea companies with good growth potential in cleantech and at the same time contributing to a more sustainable society.

North islet Tech & Life Science Investments Learn More

GOBIA Enterprises is owned by Jan G Smith who has been active in the pharmaceutical industry.

FBG Invest

Jens Mogensen is an Angel Investor.

Mikael Lonn is an Angel Investor.